Provention Bio to Present at the Virtual SVB Leerink 11th Annual Global Healthcare Conference
02/10/2022 - 07:30 AM
RED BANK, N.J. , Feb. 10, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16 th , 2022 at 10:00am EST .
The presentation will be webcast live and can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events . The webcast will be archived on the Company's website for 30 days following the presentation.
About Provention Bio, Inc.: Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including type 1 diabetes, celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.
Internet Posting of Information: Provention Bio, Inc. uses its website, www.proventionbio.com , as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.
Investor Contacts: Robert Doody , VP of Investor Relationsrdoody@proventionbio.com 484-639-7235
Sam Martin , Argot Partnersproventionbio@argotpartners.com 212-600-1902
Media Contact: Lori Rosen , LDR Communicationslori@ldrcommunications.com 917-553-6808
View original content to download multimedia:https://www.prnewswire.com/news-releases/provention-bio-to-present-at-the-virtual-svb-leerink-11th-annual-global-healthcare-conference-301479345.html
SOURCE Provention Bio, Inc.
PRVB Rankings
N/A Ranked by Stock Gains
PRVB Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
Country
US
City
Red Bank
About PRVB
Provention Bio, Inc. is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay or prevention of clinical type 1 diabetes in at-risk individuals, has been filed by the U.S. Food and Drug Administration (FDA). The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus.